| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 156.82 | 27.0% | 35.6% |
| Total Income | 157.88 | 27.4% | 35.6% |
| Expenditure | 126.23 | 25.2% | 29.7% |
| PBT | 31.65 | 41.6% | 65.8% |
| Net Profit | 25.29 | 58.0% | 74.4% |
| OPM | 24.70% | 1.11pp | 2.31pp |
| NPM | 16.02% | 3.11pp | 3.57pp |
| EPS | 24.37 | 57.9% | 74.5% |
Kwality Pharma FY26 Revenue Up ~36% YoY to ₹503 Cr
19 May 2026 · 19 May, 11:52 am
Summary
Kwality Pharmaceuticals Ltd (KPL) delivered a landmark financial performance in FY26, achieving its highest ever quarterly and annual revenues, underpinned by strong execution. For Q4 FY26, KPL reported its strongest-ever quarterly topline of ₹157.11 crore, representing a robust year-on-year growth of 35.8%. The full year FY26 closed with consolidated revenues of ₹503 crore, a significant growth of approximately 36% YoY, fulfilling a strategic revenue commitment. The company also witnessed meaningful margin expansion, with EBITDA margins improving to 24% and PAT margins expanding to 13.4%, as Profit After Tax (PAT) for FY26 grew by approximately 69% to ₹267.34 crore. Operationally, FY26 was a defining year for KPL’s global regulatory and business development initiatives, including a credit rating upgrade and strategic investments in product development.
Key Highlights
- 1
Kwality Pharmaceuticals Ltd (KPL) achieved its strongest-ever quarterly revenue of ₹157.11 crore for Q4 FY26, representing a robust year-on-year growth of 35.8%.
- 2
Consolidated revenues for the full year FY26 reached ₹503 crore, marking a significant growth of approximately 36% year-on-year compared to ₹370 crore in FY25.
- 3
Profit After Tax (PAT) for FY26 surged by approximately 69% year-on-year to ₹267.34 crore, materially outpacing revenue growth compared to ₹39.80 crore in FY25.
- 4
EBITDA margins improved by approximately 200 basis points to 24% in FY26, up from 22% in FY25, driven by an improved product mix and operating leverage benefits.
- 5
PAT margins expanded by nearly 260 basis points, improving from 10.8% in FY25 to 13.4% in FY26, reflecting enhanced operational efficiencies and tighter cost controls.
- 6
ICRA upgraded KPL's credit rating to BBB+ from B+ during the quarter, indicating a strengthened financial profile.
- 7
KPL initiated a large-scale Bioequivalence program covering more than 40 Oral Solid Dosage molecules to support global filings and maximize utilization of its OSD capacities.
Informational and educational content only. Not investment advice.